CHESTERBROOK, Pa. — September 24, 2026
Persevere Therapeutics, Inc. announced that the first patient has been enrolled and treated in MIROC-1, a Phase 2a clinical trial evaluating investigational misetionamide as a monotherapy in patients with platinum-resistant ovarian cancer (PROC). The first patient was treated at the Abramson Cancer Center of the University of Pennsylvania, one of four U.S. academic cancer centers participating in the study. Misetionamide is an investigational small molecule designed to inhibit MYC, a transcription factor involved in tumor growth and proliferation.
MIROC-1 Evaluates Misetionamide in Platinum-Resistant Ovarian Cancer
MIROC-1 is an open-label, single-arm Phase 2a study designed to evaluate the safety and efficacy of misetionamide monotherapy in patients with platinum-resistant ovarian cancer. The trial is planned to enroll 18 patients across four U.S. academic cancer centers. In addition to the University of Pennsylvania, participating institutions include Rush University Medical Center/MD Anderson Cancer Center in Chicago, Beth Israel Deaconess Medical Center/Harvard Medical School in Boston and the University of Kansas Cancer Center in Kansas City. The trial represents an early clinical evaluation of MYC inhibition in a patient population with limited treatment options.
Misetionamide Targets MYC-Driven Tumor Biology
Misetionamide is described by Persevere as a first-in-class small-molecule inhibitor of MYC, a protein that regulates cellular processes associated with cancer growth and proliferation. MYC has historically been considered difficult to target therapeutically, and Persevere is developing misetionamide as an approach to directly address MYC-driven tumor biology. The company is also evaluating the candidate through a separate development program in pancreatic cancer and holds FDA Orphan Drug Designation for pancreatic cancer. Misetionamide remains investigational, and the MIROC-1 study is intended to generate clinical safety and efficacy data needed to assess its therapeutic potential.
Advertisement
Persevere Advances Clinical Oncology Program
The initiation of MIROC-1 marks the advancement of Persevere’s misetionamide program into Phase 2a clinical development for platinum-resistant ovarian cancer. The company said the remaining participating sites are progressing toward screening, with Beth Israel Deaconess Medical Center/Harvard Medical School and the University of Kansas Cancer Center expected to begin screening within the month. Persevere also maintains an active FDA IND for its ovarian cancer program alongside its pancreatic cancer development program, as it continues evaluating MYC inhibition across cancers with significant unmet treatment needs.
Source :Persevere Therapeutics press release
